



JUL 6 1998

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Jemo Kang, Ph.D.  
President  
Princeton BioMeditech Corporation  
P.O. Box 7139  
Princeton, New Jersey 08543-7139

Re: K981882  
Cardiac STATUS™ CK-MB/Myoglobin/Troponin I Rapid Test  
Regulatory Class: II  
Product Code: JFX, MMI, DEA  
Dated: May 26, 1998  
Received: May 28, 1998


Dear Dr. Kang:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "dsmo@fdadr.cdrh.fda.gov".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical  
Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Princeton BioMeditech Corp  
Cardiac STATus™ CK-MB/Myoglobin/Troponin I Rapid Test  
510(k) Notification

510(k) Number (if Known) : Not Known at this time

Device Name : Cardiac STATus™ CK-MB/Myoglobin/Troponin I Rapid Test

**Indications for Use:**

The Cardiac STATus™ CK-MB/Myoglobin/Troponin I Rapid Test is intended for use as an *in vitro* diagnostic product for the rapid qualitative determination of CK-MB, myoglobin and troponin I in human whole blood, serum, and plasma as an aid in the diagnosis of myocardial infarction in emergency room, critical care, point of care and hospital settings.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

---

**Concurrence of CDRH, Office of Device Evaluation (ODE)**

Professional Use X

Prescription Use X  
(Per 21 CFR 801.109)

OR

Over-The Counter Use \_\_\_\_\_  
(Optional Format 1-2-96)

Carol Benzoy Alfred Montgomery  
(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number K981882